Cite
HARVARD Citation
Metro, G. et al. (2017). Optimal management of ALK-positive NSCLC progressing on crizotinib. Lung cancer. pp. 58-66. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Metro, G. et al. (2017). Optimal management of ALK-positive NSCLC progressing on crizotinib. Lung cancer. pp. 58-66. [Online].